Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults

Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults

Thirty (30) adults with limited physical function will be recruited to participate in a double-blind pilot randomized controlled crossover trial in which all participants will receive 12-weeks of twice weekly MMT treatment in the first (Phase 1) or second half (Phase 2) of the study period; during the control period, participants will receive sham treatment and will be blinded to the randomization.

Inclusion Criteria:

• physical frailty or pre-frailty, indicated by Short Physical Performance Battery Score <10;
• intact cognition indicated by a Mini-Cog Screening Test Score > 2;
• able to read and write in English; and
• access to a telephone.

Exclusion Criteria:

• active malignancy;
• neuro-degenerative disease
• active electronic implants;
• any health conditions that would prevent performing the testing and intervention procedures;
• major surgical procedures within the last 6 months;
• major change in prescription medications within the last 3 months